Abstract Library

#4534 Development of new 3D in vitro models for pancreatic neuroendocrine tumours (PanNETs)

Introduction: Current PanNET in vitro models struggle to accurately replicate the tumour’s biology and microenvironment, limiting understanding of the mechanisms underlying PanNET behaviour and drugs response.

Conference:

Presenting Author:

Authors: Battistella A, Pinos R, Barbaglio F, Capurso G, Schiavo Lena M,

Keywords: Preclinical models, Pan NET, microenvironment, bioprinting, tumour slices, drug testing,

#3857 The use of quantitative contrast-enhanced endoscopic ultrasound in the evaluation of pancreatic neuroendocrine tumors – Can we move from quality to quantity? A proof-of-concept study

Introduction: Contrast-enhanced EUS (CE-EUS) is a helpful tool for the diagnosis of pancreatic focal lesions, as pancreatic cancer (PC) and pancreatic neuroendocrine tumor (pNEN). The enhancement of the lesion after contrast medium injection is usually assessed qualitatively and arbitrarily by the endosonographer. Dedicated software has recently been developed to obtain an unbiased quantitative assessment using perfusion parameters.

Conference:

Presenting Author: Tacelli M

Authors: Tacelli M, Bina N, Capurso G, Zaccari P, Petrone M,

Keywords: CE-EUS, pNEN, artificial intelligence, pancreatic cancer, prediction,

#2852 Diagnostic Accuracy of Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) in the Evaluation of Pancreatic Neuroendocrine Neoplasms (PNEN) Grading

Introduction: Prognosis of pNENs depends on staging and grading, based on the cyto-histological Ki67 labelling; EUS-FNA is considered the gold standard technique to obtain it in pre-therapeutic setting

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tacelli M

Authors: Tacelli M, Petrone M, Capurso G, Rossi G, Archibugi L,

Keywords: Pancreatic neuroendocrine neoplasms, Grading, EUS-FNA, Endoscopic ultrasound-Fine Needle Aspiration, Ki-67, WHO, misclassification,

#2785 Inhibition of Cyclin Dependent Kinases Overcomes MYC-Driven Secondary Resistance to Everolimus in Digestive NETs

Introduction: Dysregulation of the mTOR pathway in digestive neuroendocrine tumours (d-NETs) led to the introduction of Everolimus (EVE) as treatment. EVE significantly increases PFS, but most patients acquire resistance, due to activation of feedback loops.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Capurso G

Authors: Terracciano F, Capone A, Montori A, Pilozzi E, Arcidiacono P,

Keywords: mTOR, Myc, resistance, pathway, RNA-seq,

#1344 Reassessment of Proliferative Activity at Disease Progression in Neuroendocrine Neoplasms

Introduction: Ki67 is a key factor influencing prognosis and treatment in NENs. However, whether repeating histology at time of progression of disease (PD) is debated

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Cicchese N

Authors: Cicchese N, Panzuto F, Rinzivillo M, Capurso G, Merola E,

Keywords: Ki-67, tumor progression,